ADAPT

Adipokines as Drug Targets to Combat Adverse Effects of Excess Adipose Tissue

 Coordinatore DEUTSCHE DIABETES FORSCHUNGSGESELLSCHAFT EV 

 Organization address address: AUF M HENNEKAMP 65
city: DUESSELDORF
postcode: 40225

contact info
Titolo: Mr.
Nome: Hans-Joachim
Cognome: Liebe
Email: send email
Telefono: 492113000000
Fax: 492113000000

 Nazionalità Coordinatore Germany [DE]
 Sito del progetto http://www.adapt-eu.net/
 Totale costo 3˙938˙400 €
 EC contributo 2˙980˙280 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2007-A
 Funding Scheme CP-FP
 Anno di inizio 2008
 Periodo (anno-mese-giorno) 2008-02-01   -   2012-01-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    DEUTSCHE DIABETES FORSCHUNGSGESELLSCHAFT EV

 Organization address address: AUF M HENNEKAMP 65
city: DUESSELDORF
postcode: 40225

contact info
Titolo: Mr.
Nome: Hans-Joachim
Cognome: Liebe
Email: send email
Telefono: 492113000000
Fax: 492113000000

DE (DUESSELDORF) coordinator 0.00
2    CHARITE - UNIVERSITAETSMEDIZIN BERLIN

 Organization address address: Chariteplatz 1
city: BERLIN
postcode: 10117

contact info
Titolo: Ms.
Nome: Eveline
Cognome: Fraessdorf
Email: send email
Telefono: 4930450000000
Fax: 4930450000000

DE (BERLIN) participant 0.00
3    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

 Organization address address: 101 Rue de Tolbiac
city: PARIS
postcode: 75654

contact info
Titolo: Mr.
Nome: Laurent
Cognome: Vezinhet
Email: send email
Telefono: 33562748353
Fax: 33561979752

FR (PARIS) participant 0.00
4    KAROLINSKA INSTITUTET

 Organization address address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177

contact info
Titolo: Mr.
Nome: Klas
Cognome: Karlsson
Email: send email
Telefono: 46858582434
Fax: 4687117684

SE (STOCKHOLM) participant 0.00
5    LABORATOIRE GLAXOSMITHKLINE

 Organization address address: ROUTE DE VERSAILLES 100
city: MARLY LE ROI
postcode: 78160

contact info
Titolo: Ms.
Nome: Agnes
Cognome: Meisel
Email: send email
Telefono: 33169296024
Fax: 33169296060

FR (MARLY LE ROI) participant 0.00
6    MABTECH AB

 Organization address address: Augustendalsv 19
city: STOCKHOLM
postcode: 13128

contact info
Titolo: Mr.
Nome: Kjell
Cognome: Oestrand
Email: send email
Telefono: 46855679800
Fax: 4687162701

SE (STOCKHOLM) participant 0.00
7    MEDIZINISCHE HOCHSCHULE HANNOVER

 Organization address address: Carl-Neuberg-Strasse 1
city: HANNOVER
postcode: 30625

contact info
Titolo: Mr.
Nome: Norbert
Cognome: Langhorst
Email: send email
Telefono: 495115000000
Fax: 495115000000

DE (HANNOVER) participant 0.00
8    MOLECULAR EXTENDED DISTRIBUTION IN INFORMATION TECHNOLOGY

 Organization address address: 2 Rue de Belvedere
city: PALAISEAU
postcode: 91120

contact info
Titolo: Mr.
Nome: Francois
Cognome: Delfaud
Email: send email
Telefono: 33160148743
Fax: 33160148743

FR (PALAISEAU) participant 0.00
9    PHYSIOGENEX SAS

 Organization address address: RUE PIERRE ET MARIE CURIE- PROLOGUE BIOTECH
city: LABEGE INNOPOLE
postcode: 31682

contact info
Titolo: Mr.
Nome: Guillaume
Cognome: Costecalde
Email: send email
Telefono: 33561287041
Fax: 33561287043

FR (LABEGE INNOPOLE) participant 0.00
10    STOCKHOLMS UNIVERSITET

 Organization address address: Universitetsvaegen 10
city: STOCKHOLM
postcode: 10691

contact info
Titolo: Ms.
Nome: Pia
Cognome: Bjeren-Fürstenbach
Email: send email
Telefono: 468162279
Fax: 468164595

SE (STOCKHOLM) participant 0.00
11    UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6

 Organization address address: Place Jussieu 4
city: PARIS
postcode: 75252

contact info
Titolo: Dr.
Nome: Stephanie
Cognome: Rossard
Email: send email
Telefono: 33144279712
Fax: 33144277467

FR (PARIS) participant 0.00
12    UNIVERZITA KARLOVA V PRAZE

 Organization address address: Ovocny trh 5
city: PRAHA 1
postcode: 11636

contact info
Titolo: Ms.
Nome: Jana
Cognome: Muzikova
Email: send email
Telefono: 420267000000
Fax: 420267000000

CZ (PRAHA 1) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

linked    risk    drug    skeletal    related    cells    signalling    molecules    potentially    adverse    organ    proinflammatory    muscle    adipokine    limited    adapt    cardiometabolic    diabetes    metabolic    inflammation    hormone    syndrome    abdominal    endocrine    identification    scientists    biomarkers    adipokines    cross    excess    disease    obesity    adipose    downstream    complications    insulin    combat    drugs    adipocytokines    tissue    clinical    crosstalk    symptoms    cardiac    talk    fat    health   

 Obiettivo del progetto (Objective)

'Obesity represents the major risk factor for the cardiometabolic syndrome, which is an epidemic disease that generates a severe global socio-economic burden for the public health systems. Enhanced production of proinflammatory adipocytokines by expanded adipose tissue is now considered as a key event in the pathogenesis of this syndrome. This process involves i) the systemic release of adipokines, preferentially by visceral abdominal fat and ii) the paracrine, adipokine-mediated crosstalk between periorganic fat and different organs including skeletal and cardiac muscle. Members of the ADAPT consortium have pioneered this novel view of adipose tissue as an active endocrine organ. However, there is very limited knowledge if adipokines and their downstream signalling pathways may represent “drugable” targets potentially opening new avenues to combat the devastating complications linked to obesity and the cardiometabolic syndrome. Therefore, the major goal of this project is to identify novel or existing adipocytokines as drug targets that could be used to reverse obesity-associated inflammation and adverse reactions related to excess fat, as outlined in the work programme. For this purpose the mustidisciplinary ADAPT consortium has been formed which integrates basic and clinical science, bioinformatics, in silico drug design and the specific expertise of a large pharmaceutical company. To reach the objectives, a stepwise strategy will be used including i) the identification of novel adipocytokines and the cellular sources and regulation of adipokine production, ii) the analysis of intraorgan crosstalk within adipose tissue which plays a pivotal role in adipose tissue inflammation, iii) the assessment of interorgan crosstalk with a focus on skeletal and cardiac muscle and the role of brown fat and iv) the pharmacological and clinical evaluation of adipokines as drug targets and potential biomarkers.'

Introduzione (Teaser)

Obesity is the major risk factor in cardiometabolic syndrome, a condition that puts patients at risk from heart attacks, strokes and complications of diabetes. An EU-funded project has completed research into the role of certain signalling proteins involved to facilitate the identification of new drug targets.

Descrizione progetto (Article)

One of the symptoms of cardiometabolic syndrome is inflammation in key sites such as white fat tissue, liver and immune cells. The likely culprits belong to a group of molecules called proinflammatory cytokines that set off a cascade of events that could lead to complications of obesity.

However, there is very limited information on adipocytokines and their downstream effects that may be the root cause of conditions like atherosclerosis, type 2 diabetes and rheumatoid arthritis. The 'Adipokines as drug targets to combat adverse effects of excess adipose tissue' (ADAPT) project set out to identify adipokines that could be modulated with new drugs to treat obesity-related inflammation and other adverse conditions linked with excess fat.

ADAPT scientists focused on finding new adipokines and determining the cross-talk between these compounds and other key molecular players involved in disease linked to obesity. Their findings promise to have substantial impact on the development of new anti-diabetic drugs in particular.

The team identified and characterised new adipokines and biomarkers. Chemical cross-talk was identified between macrophages (cells involved in immunity) and fat cells as well as preadipocytes, which can develop into mature fat cells.

Links between adipokine expression and different clinical symptoms of metabolic syndrome were also investigated at length. Moreover, novel assays were developed to detect signalling between fatty acids and adipokines.

Reduced insulin sensitivity is a key feature of type 2 diabetes and ADAPT scientists elucidated details on the mode of operation of hormone-sensitive lipase (HSL) in insulin resistance. The scientists also analysed the protein dipeptidyl peptidase-4 (DPP4) as a new adipokine, potentially linking obesity to the metabolic syndrome.

The storage site of fat tissue can be a crucial factor, prompting the scientists to study cardiac mass in relation to abdominal and thoracic fat deposits. They also collected data on the dynamics of adipose tissue turnover in health and disease.

The ADAPT project has classified adipose tissue as a hormone-producing tissue (endocrine organ) in its own right. As such, the molecules it produces can be up- or down-regulated, as appropriate to control their effects on other cells and tissues that result in disease. The development of new pharmaceuticals on this basis could revolutionise healthcare and the blight of obesity.

Altri progetti dello stesso programma (FP7-HEALTH)

TOXBANK (2011)

ToxBank – Supporting Integrated Data Analysis and Servicing of Alternative Testing Methods in Toxicology

Read More  

ASAPS (2012)

Sharing Age A Sharing Approach to Promoting Science

Read More  

FLUNIVAC (2013)

InFLUenza virus UNIVersal VACcine development program

Read More